Syndax Pharmaceuticals
SNDX
210 hedge funds and large institutions have $1.71B invested in Syndax Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 86 increasing their positions, 58 reducing their positions, and 24 closing their positions.
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
48% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 58
7% more funds holding
Funds holding: 196 → 210 (+14)
1.76% more ownership
Funds ownership: 102.79% → 104.55% (+1.8%)
9% more call options, than puts
Call options by funds: $16.2M | Put options by funds: $14.9M
4% less capital invested
Capital invested by funds: $1.79B → $1.71B (-$80M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| 1 |
BNP Paribas Asset Management
Paris,
France
|
+$16.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.3M |
| 3 |
FTM
First Turn Management
Del Mar,
California
|
+$11.3M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$10.3M |
| 5 |
EP
Eversept Partners
New York
|
+$10.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$26.7K | -1,300 | Closed |
|
|
EC
227
EntryPoint Capital
New York
| – | -$22.4K | -1,090 | Closed |
|
228
Pacer Advisors
Malvern,
Pennsylvania
| – | -$20.8K | -1,012 | Closed |
|
|
MG
229
Mather Group
Chicago,
Illinois
| – | -$17.8K | -750 | Closed |
|
|
RWMG
230
Redwood Wealth Management Group
Medford,
New Jersey
| – | -$5.13K | -250 | Closed |
|
|
CWM
231
CarsonAllaria Wealth Management
Glen Carbon,
Illinois
| – | -$4.48K | -218 | Closed |
|
|
BHWM
232
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$1.26K | -62 | Closed |
|
|
IC
233
Innealta Capital
Austin,
Texas
| – | -$985 | -48 | Closed |
|
|
C
234
Covestor
London,
United Kingdom
| – | -$21 | -1 | -20% |
|
SNDX Hedge Fund Activity: Q3 2024 in Review
210 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2024, worth a combined $1.71B — down 4.5% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SNDX positions and 24 closed out — a net gain of 14 holders — while 86 added to existing stakes and 58 trimmed.
The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $16.3M. The largest seller was Wellington Management Group, cutting an estimated $48.6M.
- 210 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2024, up from 196 in Q2 2024.
- Funds reported $1.71B of Syndax Pharmaceuticals stock for Q3 2024, down 4.5% quarter-over-quarter.
- 38 funds opened new Syndax Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of +14 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2024 was BNP Paribas Asset Management, an estimated $16.3M added.
- The largest Syndax Pharmaceuticals seller in Q3 2024 was Wellington Management Group, an estimated $48.6M sold.
Based on aggregated 13F filings for Q3 2024.